Six weeks of structured exercise training and hypocaloric diet increases the probability of ovulation after clomiphene citrate in overweight and obese patients with polycystic ovary syndrome: A randomized controlled trial

Human Reproduction

Volumn 25, Issue 11, 2010, Pages 2783-2791

  Palomba, S ^a   Falbo, A ^a   Giallauria, F ^b   Russo, T ^a   Rocca, M ^a   Tolino, A ^b   Zullo, F ^a   Orio, F ^c  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF NAPLES PARTHENOPE   (Italy)

Author keywords

clomiphene citrate; diet; exercise; infertility; polycystic ovary syndrome

Indexed keywords

ANDROGEN; CLOMIFENE CITRATE; INSULIN; MEDROXYPROGESTERONE ACETATE; PROGESTERONE;

ADULT; ANTHROPOMETRY; ARTICLE; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; DRUG DOSE INCREASE; EXERCISE; FEMALE; FEMALE INFERTILITY; HUMAN; INSULIN SENSITIVITY; KINESIOTHERAPY; LOW CALORY DIET; MAJOR CLINICAL STUDY; OBESITY; OVARY POLYCYSTIC DISEASE; OVULATION; OVULATION INDUCTION; PROBABILITY; RANDOMIZED CONTROLLED TRIAL;

EID: 77958146448     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/deq254     Document Type: Article

References (41)

1. Ainsworth BE, Haskell WL, Whitt MC, Irwin ML, Swartz AM, Strath SJ, O'Brien WL, Bassett DR Jr, Schmitz KH, Emplaincourt PO. Compendium of physical activities: an update of activity codes and MET intensities. Med Sci Sports Exerc 2000;32:S498-S504.
2. Anderson JW, Konz EC, Frederich RC, Wood CL. Long-term weight-loss maintenance: a meta-analysis of US studies. Am J Clin Nutr 2001; 74:579-584.
3. Balen AH, Laven JS, Tan SL, Dewailly D. Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update 2003;9:505-514.
4. Branigan EF, Estes MA A randomized clinical trial of treatment of clomiphene citrate-resistant anovulation with the use of oral contraceptive pill suppression and repeat clomiphene citrate treatment. Am J Obstet Gynecol 2003; 188:1424-1428.
5. Brown J, Farquhar C, Beck J, Boothroyd C, Hughes E. Clomiphene and anti-oestrogens for ovulation induction in PCOS. Cochrane Database Syst Rev 2009;4:CD002249.
6. Clark AM, Ledger W, Galletly C, Tomlinson L, Blaney F, Wang X, Norman RJ. Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Hum Reprod 1995;10:2705-2712.
7. Clark AM, Thornley B, Tomlinson L, Galletley C, Norman RJ. Weight loss in obeseinfertilewomen resultsin improvementin reproductiveoutcomefor all forms offertility treatment. Hum Reprod 1998; 13:1502-1505.
8. Cussons AJ, Stuckey BG, Walsh JP, Burke V, Norman RJ. Polycystic ovarian syndrome: marked differences between endocrinologists and gynaecologists in diagnosis and management. Clin Endocrinol (Oxf) 2005;62:289-295.
9. Dickey RP, Holtkamp DE. Development, pharmacology and clinical experiencewith clomiphenecitrate. Hum Reprod Update 1996;2:483-506.
10. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440-1447.
11. Gysler M, March CM, Mishell DR Jr, Bailey EJ. A decade's experience with an individualized clomiphene treatment regimen including its effect on the postcoital test. Fertil Steril 1982;37:161-167.
12. Hoffman LK, Ehrmann DA Cardiometabolic features of polycystic ovary syndrome. Nat Clin Pract Endocrinol Metab 2008;4:215-222.
13. Huber-Buchholz MM, Carey DG, Norman RJ. Restoration ofreproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab 1999;84:1470-1474.
14. Imani B, Eijkemans MJC, te Velde ER, Habbema JD, Fauser BCJM. Predictors of patients remaining anovulatory during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. J Clin Endocrinol Metab 1998;83:2361-2365.
15. Imani B, Eijkemans MJC, te Velde ER, Habbema JDF, Fauser BCJM. Predictors of chances to conceive in ovulatory patients during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. J Clin Endocrinol Metab 1999;84:1617-1622.
16. Kousta E, White DM, Franks S. Modern use of clomiphene citrate in induction ofovulation. Hum Reprod Update 1997;3:359-365.
17. Legro RS, Myers E. Surrogate end-points or primary outcomes in clinical trials in women with polycystic ovary syndrome? Hum Reprod 2004; 19:1697-1704.
18. Moher D, Schulz KF, Altman D; CONSORT Group (Consolidated Standards of Reporting Trials). The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials.JAm Med Assoc 2001;285:1987-1991. (Pubitemid 32366951)
19. Moran LJ, Noakes M, Clifton PM, Norman RJ. The use of anti-mullerian hormone in predicting menstrual response after weight loss in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2007a;92:3796-3802. (Pubitemid 47607625)
20. Moran LJ, Noakes M, Clifton PM, Wittert GA, Le Roux CW, Ghatei MA, Bloom SR, Norman RJ. Postprandial ghrelin, cholecystokinin, peptide YY, and appetite before and after weight loss in overweight women with and without polycystic ovary syndrome. Am J Clin Nutr 2007b; 86:1603-1610. (Pubitemid 350232173)
21. Moran L, Pasquali R, Teede HJ, Hoeger KM, Norman RJ. Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. Fertil Steril 2009;92:1966-1982.
22. National Heart, Lung, and Blood Institute/National Institutes of Diabetes and Digestive and Kidney diseases. Clinical Guidelines on the Identification, Evaluation and Treatment ofOverweight and Obesity in Adults. The Evidence Report. Bethesda: National Institutes ofHealth, 1998;1-228.
23. National Institute for Clinical Excellence. Fertility Assessment and Treatment For People with Fertility Problems. A Clinical Guideline. London: RCOG Press, 2004.
24. Norman RJ, Noakes M, Wu R, Davies MJ, Moran L, Wang JX. Improving reproductive performance in overweight/obese women with effective weight management. Hum Reprod Update 2004; 10:267-280.
25. Palomba S, Orio F Jr, Russo T, Falbo A, Cascella T, Colao A, Lombardi G, Zullo F. Is ovulation induction still a therapeutic problem in patients with polycystic ovary syndrome?J Endocrinol Invest 2004;27:796-805.
26. Palomba S, Russo T, Orio F Jr, Falbo A, Manguso F, Sammartino A, Tolino A, Colao A, Carmina E, Zullo F. Uterine effects of clomiphene in women with polycystic ovary syndrome: a prospective case-control study. Hum Reprod 2006a;21:2823-2829. (Pubitemid 44566993)
27. Palomba S, Orio F Jr, Falbo A, Russo T, Tolino A, Zullo F. Effects of metformin and clomiphene citrate on ovarian vascularity in patients with polycystic ovary syndrome. Fertil Steril 2006b;86:1694-1701.
28. Palomba S, Giallauria F, Falbo A, Russo T, Oppedisano R, Tolino A, Colao A, Vigorito C, Zullo F, Orio F. Structured exercise training programme versus hypocaloric hyperproteic diet in obese polycystic ovary syndrome patients with anovulatory infertility: a 24-week pilot study. Hum Reprod 2008;23:642-650.
29. Palomba S, Falbo A, Zullo F. Management strategies for ovulation induction in women with polycystic ovary syndrome and known clomifene citrate resistance. Curr Opin Obstet Gynecol 2009;21:465-473.
30. Pasquali R, Gambineri A, Pagotto U. The impact ofobesity on reproduction in women with polycystic ovary syndrome. BJOG 2006; 13:1148-1159. (Pubitemid 44401208)
31. Ramlau-Hansen CH, Thulstrup AM, Nohr EA, Bonde JP, Sorensen TI, Olsen J. Subfecundity in overweight and obese couples. Hum Reprod 2007;22:1634-1637.
32. Roeykens J, Rogers R, Meeusen R, Magnus L, Borms J, de Meirleir K. Validity and reliability in a Flemish population of the WHO-MONICA Optional Study of Physical Activity Questionnaire. Med Sci Sports Exerc 1998;30:1071-1075.
33. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19:41-47.
34. Stamets K, Taylor DS, Kunselman A, Demers LM, Pelkman CL, Legro RS. A randomized trial of the effects of two types ofshort-term hypocaloric diets on weight loss in women with polycystic ovary syndrome. Fertil Steril 2004;81:630-637.
35. The ESHRE Capri Workshop Group. Anovulatory infertility. Hum Reprod 995;10:1549-1553.
36. The Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Hum Reprod 2008;23:462-477.
37. Thomson RL, Buckley JD, Moran LJ, Noakes M, Clifton PM, Norman RJ, Brinkworth GD. The effect of weight loss on anti-Müllerian hormone levels in overweight and obese women with polycystic ovary syndrome and reproductive impairment. Hum Reprod 2009; 24:1976-1981.
38. Vigorito C, Giallauria F, Palomba S, Cascella T, Manguso F, Lucci R, De Lorenzo A, Tafuri D, Lombardi G, Colao A et al. Beneficial effects of a three-month structured exercise training program on cardiopulmonary functional capacity in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2007;92:1379-1384.
39. Willett W. Food Frequency Methods. Nutritional Epidemiology, 2nd edn. Oxford, UK: Oxford University Press, 1998.
40. World Health Organization. Current Practices and Controversies in Assisted Reproduction. Geneva, Swiss: World Health Organization Press, 2002.
41. Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome; towards a rational approach. In: Dunaif A, Givens JR, Haseltine F (eds). Polycystic Ovary Syndrome. Boston: Blackwell Scientific, 1992;377-384.